Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes. (PubMed, Nat Rev Nephrol) - Sep 6, 2026 - "Investigational treatments that have targeted inflammation include inhibition of apoptosis signal-regulating kinase-1 (ASK1) by selonsertib, Janus kinase (JAK) 1/2 inhibition with baricitinib, protein kinase C-β (PKCβ) inhibition with ruboxistaurin, nuclear factor erythroid 2-related factor 2 (Nrf2) activation with bardoxolone, phosphodiesterase inhibition with pentoxifylline and monoclonal antibodies against IL-1β and IL-6. Furthermore, proven therapies for CKD, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid antagonists, possess anti-inflammatory properties that might contribute to their previously established clinical benefits."
Journal • Review • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Inflammation • Nephrology • Renal Disease • CRP • IL1B • IL6 • PRKCB
|
|
Ann Marie Navar; Brendon L Neuen; Juan Jesús Carrero; Katherine R Tuttle; Mehmet Kanbay; Nikolaus Marx; Paul M Ridker; Peter Rossing; Radica Z Alicic; Sidar Copur; Vlado Perkovic
|